title: Endoscopic treatment of symptomatic refluxing renal transplant ureteroneocystostomies in children.
abstract: To present a multi-center experience with the use of Dx/HA copolymer for treatment of symptomatic refluxing renal transplant UNC in children. A multi-center, retrospective chart review was performed. Eleven patients with a mean age of eight yr underwent renal transplantation with an anti-refluxing UNC. Data were collected to determine the safety and effectiveness of the procedure and to identify possible predictors of success. Endoscopic treatment was successful in one of five males and five of six females, for an overall success rate of 54.5%. The etiology of renal failure was associated with success of treatment, with 4/6 (67%) patients with upper tract pathology demonstrating resolution of the VUR, as compared with one of three (33%) patients with lower tract pathology. Male patients had a higher incidence of lower tract pathology. No complications were associated with the endoscopic procedure. Endoscopic injection of Dx/HA remains a safe option for the treatment of symptomatic refluxing transplant UNC in children. Although the success rate is lower than that seen in the treatment of primary VUR, the minimally invasive nature and safety of this technique may offer advantages over open reconstruction of the refluxing transplant ureter.
authors.affiliation: Pediatric Urology, Seattle Children's, Seattle, WA, USA.
authors.forename: Vijaya M
authors.initials: VM
authors.lastname: Vemulakonda
authors.forename: Martin A
authors.initials: MA
authors.lastname: Koyle
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Lendvay
authors.forename: Michael C
authors.initials: MC
authors.lastname: Risk
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Kirsch
authors.forename: Earl Y
authors.initials: EY
authors.lastname: Cheng
authors.forename: Lars J
authors.initials: LJ
authors.lastname: Cisek
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Campbell
mesh_terms: D001672:Biocompatible Materials / Q000008:administration & dosage*; D002648:Child; D003911:Dextrans / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007267:Injections; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D012189:Retrospective Studies; D018666:Ureteroscopy; D014718:Vesico-Ureteral Reflux / Q000209:etiology / Q000628:therapy*
chemical_list: D001672:Biocompatible Materials; D003911:Dextrans; C487487:dextranomer-hyaluronic acid copolymer; D006820:Hyaluronic Acid